DORMANT studio
localhost:3000

Opportunity radar

4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05

Showing50 of 97,052
Free-text
CPC starts with (comma sep)
Min fwd citations
Clear
Patent #TitleAssetsIssuedExpiresFwd citesScore
12618065MiRNA detargeting system for tissue specific interference🖼🧊📄§2026-05-052038-10-02031
12618066Promoter having high activity in activated T-cell🖼🧊📄§2026-05-052040-11-13031
12618076Methods of engineering platelets for targeting circulating tumor cells🖼🧊📄§2026-05-052040-09-30031
12618082Engineered muscle targeting compositions🖼🧊📄§2026-05-052042-03-29031
12617762Carboxy derivatives with antiinflamatory properties🖼🧊📄§2026-05-052040-12-23031
12617790Mitragynine analogs and uses thereof🖼🧊📄§2026-05-052041-06-24031
12617805Codrug that disintegrates in intestine, preparation therefor, and use thereof🖼🧊📄§2026-05-052041-07-19031
12617807Long lasting opioid reversal using hydrogen peroxide-induced release in blood🖼🧊📄§2026-05-052042-04-01031
12617809Cardioprotective lipid and method of use🖼🧊📄§2026-05-052042-09-22031
12617811HPK1 inhibitors and uses thereof🖼🧊📄§2026-05-052041-07-02031
12617812Platinum(IV) complexes, methods of manufacture, compositions containing, and methods of use thereof🖼🧊📄§2026-05-052042-05-25031
12617820Engineered coronavirus spike (s) protein and methods of use thereof🖼🧊📄§2026-05-052041-05-28031
12617822Arc-based capsids and uses thereof🖼🧊📄§2026-05-052042-10-13031
12617826CLEC2 fusion protein and uses thereof🖼🧊📄§2026-05-052041-09-29031
12617828Genetically modified immune cell, preparation method therefor, and application🖼🧊📄§2026-05-052040-05-06031
12617831Peptide targeting GIP and GLP-2 receptors for treating bone disorders🖼🧊📄§2026-05-052040-02-21031
12617833Tethered interleukin-15 and interleukin-21🖼🧊📄§2026-05-052039-02-07031
12617832Genetic engineering of B cell receptors and uses thereof in antigen-induced antibody secretion🖼🧊📄§2026-05-052041-03-12031
12617836Tumor environment specific expression of effector genes🖼🧊📄§2026-05-052042-03-21031
12617837Composition for use in treatment of allergic diseases🖼🧊📄§2026-05-052040-02-28031
12617839Factor VIII chimeric proteins and uses thereof🖼🧊📄§2026-05-052041-11-05031
12617841Nucleic acid antibody constructs for use against respiratory syncytial virus🖼🧊📄§2026-05-052039-01-31031
12617850Treatment of PD-L1-positive melanoma using an anti-PD-1 antibody🖼🧊📄§2026-05-052042-03-22031
12617849Antigen specific CD19-targeted CAR-T cells🖼🧊📄§2026-05-052040-04-29031
12617851TREM2 antibodies and uses thereof🖼🧊📄§2026-05-052042-05-05031
12617856Protease-cleavable substrates and methods of use thereof🖼🧊📄§2026-05-052045-03-17031
12617864Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof🖼🧊📄§2026-05-052042-04-12031
12617866Humanized antibodies to mucin-16 and methods of use thereof🖼🧊📄§2026-05-052040-05-07031
12617867Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof🖼🧊📄§2026-05-052039-09-25031
12617868Activation of (Na++K+)-ATPase inhibits platelet aggregation and prevents thrombosis🖼🧊📄§2026-05-052042-11-08031
12617870Methods of reversing ticagrelor activity🖼🧊📄§2026-05-052039-09-20031
12617873Method of purifying polysaccharides🖼🧊📄§2026-05-052040-11-30031
12617887Resin composition for stereolithography🖼🧊📄§2026-05-052041-02-09031
12617903Process for producing a composition comprising a crosslinked hydrogel🖼🧊📄§2026-05-052040-12-08031
12618074CD40 specific DNA aptamers as vaccine adjuvants🖼🧊📄§2026-05-052040-04-13031
12618031Delivery devices🖼🧊📄§2026-05-052041-06-24031
12618048Dual CAR-T cells🖼🧊📄§2026-05-052041-07-30031
12617772Hydroxypyridine HSD17B13 inhibitors and uses thereof🖼🧊📄§2026-05-052042-04-04031
12617773Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators🖼🧊📄§2026-05-052041-04-30031
12617774Substituted indole compounds and methods of use thereof🖼🧊📄§2026-05-052045-05-30031
12617799Pyrazolopyrimidinone compounds🖼🧊📄§2026-05-052042-03-25031
12617853Low pH pharmaceutical composition comprising T cell engaging antibody constructs🖼🧊📄§2026-05-052038-02-02031
12617854Humanized or chimeric CD3 antibodies🖼🧊📄§2026-05-052042-05-09031
12616755Antifungal quercetin conjugates, methods of preparation and uses thereof🖼🧊📄§2026-05-052045-10-08031
12616652Lenses for treating ocular diseases and preparation method thereof🖼🧊📄§2026-05-052042-12-29031
12616745Influenza virus backbone🖼🧊📄§2026-05-052040-06-05031
12616733XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions🖼🧊📄§2026-05-052041-02-10031
12616714Enhanced oligonucleotides for modulating FUBP1 expression🖼🧊📄§2026-05-052041-06-25031
12616749Methods for treatment of psoriasis with an anti-oxLDL antibody🖼🧊📄§2026-05-052044-06-21031
12616685Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C9 substrates🖼🧊📄§2026-05-052041-05-26031